Received May 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| YF | YELLOW FEVER (YF-VAX) | SANOFI PASTEUR | UNK | UK324AB | SC / LA |
inappropriate use/received a Yellow Fever Vaccine. Later it was confirmed they received Stamaril in 2020 with no AE; Initial information received on 02-Apr-2026 regarding an unsolicited valid non-serious case received from a nurse (healthcare professional). This case involves a 17-year-old male patient who received Yellow Fever Vaccine - (YF-Vax), but he had already received Stamaril in 2020 with no adverse effects. The patient's past medical history, medical treatment(s), vaccination(s), family history were not provided. Patient past vaccination included stamaril in 2020 for immunisation. On 28-Mar-2026, the patient received a 0.5 mL dose (once) of Yellow Fever Vaccine, Solution for injection (batch: UK324AB, expiry: 30-Nov-2028) (strength: standard) via subcutaneous route in left arm for immunization, but he had already received Stamaril in 2020 with no adverse effects. [Extra dose administered] [Latency: same day]. It was reported that, "Nurse vaccinated a family of 4 with YF-VAX on Saturday. At that time the family was not aware that they had received a Yellow Fever Vaccine. Later it was confirmed they received Stamaril in 2020" Action taken: Not reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.